| |
Type 2 diabetic patients |
Control |
p value |
| Number |
23 |
13 |
|
| Age |
58 ± 2.7 |
52 ± 2 |
0.975 |
| Gender (males/females) |
18/5 |
5/8 |
0.169 |
| BMI (kg/m2) |
21 ± 0.3 |
21 ± 0.5 |
1.000 |
| HbA1c (%) (NGDP) |
9.1 ± 0.30 |
5.4 ± 0.01 |
<0.001 |
| Plasma glucose (mg/dL) |
151 ± 9 |
92 ± 2 |
<0.001 |
| Serum immunoreactive insulin (μU/mL) |
5.2 ± 0.6 |
3.7 ± 0.6 |
0.163 |
| HOMA-R |
1.9 ± 0.2 |
0.8 ± 0.1 |
0.001 |
| HOMA-β (%) |
25.1 ± 3.4 |
80.1 ± 5.1 |
0.001 |
| Serum immunoreactive C-peptide (ng/mL) |
1.7 ± 0.1 |
1.4 ± 0.1 |
0.073 |
| Plasma immunoreactive active GLP-1 like substance (pmol/L) |
4.0 ± 0.5 |
2.6 ± 0.5 |
0.063 |
| Duration of diabetes from discovery (year) |
9.2 ± 1.5 |
|
|
| Retinopathy (NDR/SDR//PPDR/PDR) |
19/1/0/3 |
|
|
| Peripheral neuropathy |
8 |
|
|
| Nephropathy (Normo/Micro/Macro) |
17/5/1 |
|
|
| Macroangiopathy (asymptomatic) |
3 |
|
|
| Diabetic treatment (α-GI/BG/TZD/SU) |
1/15/12/12 |
|
|
| Dyslipidemia treatment |
2 |
|
|
| Hypertension treatment |
5 |
|
|
